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Abstract MR spectroscopy has demonstrated extrahip-
pocampal NAA/(Cr?Cho) reductions in medial temporal
lobe epilepsy with (TLE-MTS) and without (TLE-no)
mesial temporal sclerosis. Because of the limited brain
coverage of those previous studies, it was, however, not
possible to assess differences in the distribution and extent
of these abnormalities between TLE-MTS and TLE-no.
This study used a 3D whole brain echoplanar spectroscopic
imaging (EPSI) sequence to address the following ques-
tions: (1) Do TLE-MTS and TLE-no differ regarding
severity and distribution of extrahippocampal NAA/
(Cr?Cho) reductions? (2) Do extrahippocampal NAA/
(Cr?Cho) reductions provide additional information for
focus lateralization? Forty-three subjects (12 TLE-MTS, 13
TLE-no, 18 controls) were studied with 3D EPSI. Statis-
tical parametric mapping (SPM2) was used to identify
regions of signiﬁcantly decreased NAA/(Cr?Cho) in TLE
groups and in individual patients. TLE-MTS and TLE-no
had widespread extrahippocampal NAA/(Cr?Cho) reduc-
tions. NAA/(Cr?Cho) reductions had a bilateral fronto-
temporal distribution in TLE-MTS and a more diffuse, less
well deﬁned distribution in TLE-no. Extrahippocampal
NAA/(Cr?Cho) decreases in the single subject analysis
showed a large inter-individual variability and did not
provide additional focus lateralizing information. Extra-
hippocampal NAA/(Cr?Cho) reductions in TLE-MTS and
TLE-no are neither focal nor homogeneous. This reduces
their value for focus lateralization and suggests a hetero-
geneous etiology of extrahippocampal spectroscopic met-
abolic abnormalities in TLE.
Keywords Temporal lobe epilepsy  Mesial temporal
sclerosis  NAA  Spectroscopy
Introduction
Temporal lobe epilepsy (TLE) is the most common form of
partial epilepsy. Two types of non-lesional medial TLE are
distinguished based on imaging and histopathological
ﬁndings: (1) TLE with mesial temporal lobe sclerosis
(TLE-MTS, about 60–70%), which is characterized by an
atrophied hippocampus with MR signal abnormalities and
severe neuronal loss in the histological examination, and
(2) TLE with a normal appearing hippocampus on the MRI
(TLE-no, about 30–40%) and no or mild neuronal loss in
the histological examination. The differences between the
two TLE types, however, are not restricted to the hippo-
campus and its appearance in the MRI or histopathological
preparation. Recent neuroimaging studies have shown that
structural and functional abnormalities exist beyond the
hippocampus and even beyond the temporal lobe, and that
the two groups not only differ regarding severity of these
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distribution [1–5]. These ﬁndings, together with other
crucial clinical differences between TLE-MTS and TLE-
no, e.g. history of febrile seizures, age at onset of epilepsy,
initial ictal zone [6] or success of epilepsy surgery [7, 8],
suggest that TLE-no is more than just a milder form of
TLE-MTS but eventually even a distinct entity of TLE.
MR spectroscopy allows the non-invasive measurement
of N-acteyl-aspartate (NAA) (marker of neuronal viability
andfunctionality), creatine/phosphocreatine (Cr) (marker of
energy metabolism), and choline compounds (Cho) (marker
of cell membrane integrity), simultaneously and thus pro-
vides information about various important aspects of the
brain metabolism. The typical spectroscopic hallmark of the
epileptogenic focus is an NAA reduction which is generally
thought to represent mostly neuron loss [9, 10], while Cho
and Cr are unchanged [11]. Using multiple single voxel
spectroscopy or multi-slice spectroscopic imaging tech-
niques, it has been shown that NAA reductions are not
restricted to the focus in TLE but can be found in extra-
hippocampal and extratemporal regions as well [12, 13].
Because of their limited brain coverage, these previous
studies were not able to conclusively assess if the distribu-
tion and/or extent of these extrafocal NAA reductions
differs between TLE-MTS and TLE-no. The recent devel-
opment of 3D spectroscopic imaging sequences, which
providespectroscopicinformationfromthewholebrain,has
changed this [14]. Using such a sequence [15] we addressed
the following speciﬁc aims: (1) Conﬁrm the ﬁndings of
previous studies showing that extrahippocampal/extra-
temporal NAA reductions exist in unilateral TLE and to test
if TLE-MTS and TLE-no differ regarding the distribution
andseverityoftheseabnormalities.Basedonrecentﬁndings
in structural MRI [16], it was assumed that NAA reductions
in TLE-MTS would show a mesial-temporal, temporal-
posterior to occipital distribution and in TLE-no a temporo-
lateral distribution. (2) Test if severity and extent of
extrahippocampal NAA reductions provide additional
informationforfocuslateralizationinTLE-MTSorTLE-no.
It was assumed that they would be more prominent in the
hemisphere and/or lobe containing the epileptogenic focus.
Methods
Study population
The committees of human research at the University of
California, San Francisco (UCSF), California Paciﬁc Med-
icalCenter,SanFrancisco(CPMC)andVAMedicalCenter,
San Francisco approved the study, and written informed
consent was obtained from each subject according to the
Declaration of Helsinki. Twenty-ﬁve consecutive patients
suffering from therapy resistant temporal lobe epilepsy with
unilateral seizure onset who were evaluated for epilepsy
surgery and agreed to undergo the additional special
research imaging and spectroscopy protocol at 4 T were
recruited between mid 2005 and the end of 2009 from the
Paciﬁc Epilepsy Program, CPMC and the Northern Cali-
fornia Comprehensive Epilepsy Center, UCSF. Twelve
(mean age 39.6 ± 11.5; left TLE/right TLE: 7/5, females/
males 8/4) had evidence for mesial temporal lobe sclerosis
(MTS) on their MRIs (TLE-MTS) and the remaining 13
(mean age 40.5 ± 9.5; left TLE/right TLE: 8/5; females/
males: 7/6) had normal appearing hippocampi (TLE-no).
The ﬁndings regarding presence/absence of MTS were
conﬁrmed using subﬁeld volumetry in high resolution T2
weighted images [17]. The two groups differed regarding
mean age at onset of epilepsy (TLE-MTS: 11.2 ± 10.0
years; TLE-no: 26.2 ± 12.4 years, p = 0.003) and mean
duration of epilepsy (TLE-MTS: 28.9 ± 15.6 years; TLE-
no: 14.8 ± 12.4 years; p = 0.02). The identiﬁcation of the
epileptogenic focus was based on seizure semiology and
prolonged ictal and interictal Video/EEG/Telemetry (VET)
in all patients. In order to qualify as unilateral TLE, all
seizures (average 4.8 ± 2.4/patient) recorded during this
time had to be typical for the patient, show EEG features
consistent with mesial temporal onset and arise from the
same side. All TLE subjects reported having been seizure
free for at least 24 h before the 4 T study. The seizure fre-
quency was determined by calculating the mean frequency/
monthofallseizuretypesrecordedbythepatientinthethree
months before the research MR exam. Table 1 displays the
patient characteristics. The control population consisted of
18 healthy age-matched volunteers (mean age 33.5 ± 10.0;
females/males: 13/5).
MRI acquisition
Allstudies were performed onaBruker MedSpec 4Tsystem
controlledbyaSiemensTrio
TMconsoleandequippedwitha
USA instruments eight channel array coil. The following
sequences, which were part of a larger research imaging and
spectroscopy protocol, were acquired: (1) volumetric T1-
weighted gradient echo MRI (MPRAGE) TR/TE/
TI = 2,300/3/950 ms, 7
o ﬂip angle, 1.0 9 1.0 9 1.0 mm
3
resolution,acquisitiontime5 min.(2)3Dechoplanarwhole
brain spectroscopic imaging (EPSI) TR/TE/TI = 1,780/
45/280 ms,FOV = 280 9 280 9 180 mm
3(x,y,z),spatial
matrix: 50 9 50 9 18 points, spectral bandwidth =
1,667 Hz, 800 spectral points. Metabolite and water refer-
ence data was acquired in an interleaved fashion with the
delay between metabolite and water reference excitations of
TRWR = 550 ms.TotalEPSIacquisitiontime:27 min.This
spectroscopic imaging sequence allows for the detection of
the major brain metabolites NAA, Cr and Cho.
604 J Neurol (2011) 258:603–612
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EPSI postprocessing
A B0 map was derived from the water reference image.
The water reference data was then zero-ﬁlled from
50 9 50 9 18 to 64 9 64 9 24 points, and a spatial
apodization using a Gaussian ﬁlter was applied before
performing of a four-dimensional spectral FT and B0
correction [18]. The resulting image was used to generate a
brain mask which was applied to the metabolite data to
avoid ﬁtting of regions of no interest. The metabolite data
was corrected for chemical shift artifact, echo averaged and
the residual water signal was reduced by applying a ﬁnite
impulse response (FIR) ﬁlter. Spectral processing of the
metabolite data included zero ﬁlling to 512 points, lipid k-
space extrapolation and Gaussian apodization with a line
broadening of 2 Hz before performing a four-dimensional
FT and spectral ﬁtting with SITOOLS [19] (cf. Fig. 1). A
binary map containing only voxels of acceptable quality
(QC map) was generated using linewidth (between
3–21.3 Hz) and ﬁt accuracy (ﬁts with residual sum squares
outside the 95 percentile distribution of residuals from all
ﬁts were rejected) [18, 20] as main criteria. Intensity
images for each metabolite of interest (NAA, Cr and Cho)
were derived from the ﬁtted metabolite data and used to
calculate NAA/(Cr?Cho) maps. NAA/(Cr?Cho) has been
found to be very sensitive to the type of metabolic abnor-
mality observed in TLE [13] and has (compared to single
metabolite maps) the additional advantage that it does not
require an intensity non uniformity correction of the
spectral data. Voxels with NAA/(Cr?Cho)[4 indicating
an insufﬁcient suppression/extraction of the skull lipid
signal were excluded. The ﬁnal QC map was applied to the
resulting ratio map to eliminate spectra with insufﬁcient
quality.
Table 1 Patient characteristics
Pat no. Age/sex 4 T MRI Focus Onset Duration Risk factors Histo/outcome
1 35/m L MTS L temp atrophy L mesial temp 4 31 L temp/MTS/I/24
2 50/f L MTS L temp atrophy L mesial temp 2 49 FS L temp/MTS/I/6
3 35/f L MTS L mesial temp 9 26 L temp/MTS/II/12
4 38/f L MTS L mesial temp 6 32 FS na
5 53/f L MTS L mesial temp 28 26 Infection L temp/MTS/I/6
6 32/f L MTS L mesial temp 24 9 Infection L temp/MTS/IV/6
7 49/f R MTS R mesial temp 7 42 R temp/MTS/I/24
8 23/f R MTS R mesial temp 5 18 Infection na
9 33/f L MTS L mesial temp 14 20 na
10 63/m R MTS R mesial temp 6 58 FS na
11 32/m R MTS R mesial temp 28 4 R temp/MTS/I/9
12 32/m R MTS, subtle WMH R mesial temp 1 32 Infection R temp/MTS/I/4
13 39/m Small cyst L temp pole L mesial temp 29 11 na
14 27/f Normal L mesial temp 10 17 na
15 33/f L front WMH L mesial temp 10 24 L temp/MTS/I/18
16 38/f Normal L mesial temp 37 2 na
17 22/f Normal R mesial temp 22 0 na
18 45/f Normal R mesial temp 31 15 na
19 45/m WMH R mesial temp 30 16 Posttrauma R temp/norm/I/18
20 41/m Normal R mesial temp 40 1 Posttrauma na
21 45/m Normal R mesial temp 38 8 na
22 57/m Normal L mesial temp 13 44 na
23 53/f Normal L mesial temp 47 6 na
24 42/f Normal L mesial temp 21 21 na
25 39/m Normal L mesial temp 13 27 L temp/norm/I/24
Age/sex age at examination/sex, f female, m male, MTS mesial temporal sclerosis at 1.5 T, Norm normal MRI at 1.5 T, R right, L left, temp
temporal, WMH white matter hyperintensities, Onset age at onset, Duration duration of epilepsy, FS febrile seizure, Infection history of
encephalitis/meningitis without temporal relationship to onset of seizures, perinatal perinatal complications, posttrauma mild closed head trauma
in history without temporal relationship to onset of seizures, histo histology, surgery epilepsy surgery, na no. surgery, Outcome latest outcome
using Engel’s classiﬁcation is given in roman numerals, follow-up in months is given in arabic numerals
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All T1 images were segmented in gray, white and CSF
tissue maps using expectation maximization segmentation
(EMS) [21, 22].
Combination of structural and EPSI data
The T1 images were co-registered (six afﬁne, mutual
information [23]), down-sampled to the resolution of the
EPSI water reference image and the resulting transforma-
tion matrices were applied to the T1 image and the gray
matter map. The resulting down-sampled gray matter maps
were spatially normalized to a previously generated cus-
tomized symmetrical gray matter prior in ICBM (Interna-
tional Consortium for Brain Mapping) space using the
spatial normalization algorithm in statistical parametric
mapping 2 (SPM2) (Wellcome Department of Cognitive
Neurology, http://www.ﬁl.ion.ucl.ac.uk) running MAT-
LAB 6.1 (The MathWorks, Natick, MA, USA). The
resulting transformations were then applied to the NAA/
(Cr?Cho) map with and without QC, the QC map, the T1
image co-registered to the EPSI and the gray matter map.
The resulting spatially normalized maps were re-sampled
to a 1 9 19 1 mm resolution.
Data analysis
Two approaches were used for data analysis: (1) Group
analysis: each TLE subgroup was compared to the control
group and with each other to identify regions with
decreased NAA/(Cr?Cho). In order to allow for the com-
bination of left and right onset TLE patients, the NAA/
(Cr?Cho) maps of all right TLE were side ﬂipped so that
the hemisphere with the epileptogenic focus was on the left
side in all patients. To account for physiological right/left
hemispheric differences, all control NAA/(Cr?Cho) maps
were also side-ﬂipped and both versions were used for the
group comparisons. (2) Single subject analysis: each indi-
vidual TLE subject was compared to the control group and
a map with regions of signiﬁcantly reduced NAA/
(Cr?Cho) generated using SPM2.
Statistical analysis
Group analysis
SPM2 was used to identify regions with signiﬁcantly
decreased NAA/(Cr?Cho) in TLE-MTS compared to
controls, in TLE-no compared to controls, and in TLE-
MTS compared to TLE-no (compare populations:1 scan/
Fig. 1 Raw 3D EPSI with representative spectra from a TLE-MTS
patient with a right sided focus. All displayed spectra passed the
automated quality control. Spectrum 28 has been enlarged and the
peaks of the main metabolites are labelled. NAA N-acetyl-aspartate,
Cr creatine/phosphocreatine, Cho choline compounds
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123subject (ANCOVA), age as nuisance variable, threshold for
signiﬁcance at voxel level p\ 0.001 and p\ 0.05 cor-
rected at cluster level).
Single subject analysis
SPM2 was used to localize regions of metabolic abnor-
malities in individual TLE subjects by performing a t test
in which each TLE subject was compared with all control
subjects [compare populations: 1 scan/subject (two-sample
t test)]. The threshold for statistical signiﬁcance was
deﬁned as p\0.005 at voxel level and p\0.05 at cluster
level. These thresholds had been determined empirically by
comparing each control with all remaining controls and
then choosing the threshold at which none of the controls
except one had clusters with abnormally low NAA/
(Cr?Cho). In this control, these clusters persisted even
when higher thresholds (FDR p\0.05) were applied. The
localization of each cluster was based on the coordinates of
the voxel with the maximal t value. The region with the
largest cluster of signiﬁcantly reduced NAA/(Cr?Cho) was
arbitrarily determined to represent the ‘‘focus as deter-
mined by 3D EPSI’’. If the ‘‘focus as determined by 3D
EPSI’’ was concordant with the epileptogenic temporal
lobe as identiﬁed by VET, the EPSI focus identiﬁcation
was considered to be ‘‘correct’’. EPSI identiﬁcation of the
epileptogenic temporal lobe instead of the hippocampus
was chosen because the spectral quality in the hippocam-
pus was often adversely affected by the susceptibility
artifacts typical for the basal temporal lobe. This resulted in
the loss of the spectra from the head and anterior two-thirds
of the body of the hippocampus (on average 26±14% of
the hippocampal voxels fulﬁlled the quality criteria), i.e.,
the region where previous studies had shown the most
prominent abnormalities in TLE [11]. Because of this,
spectral information from the hippocampal tail was lumped
together with the temporal lobe for ‘‘focus determination
by EPSI’’. Mann–Whitney tests and Fisher’s exact test
were used to compare indices of epilepsy severity and EPSI
brain coverage between TLE with and without clusters of
abnormally low NAA/(Cr?Cho). Holms’ test was used to
correct for multiple comparisons.
Results
Group analysis
Figure 2 displays the results of the group analysis. NAA/
(Cr?Cho) abnormalities in TLE-MTS had a bilateral
temporo-occipital distribution. Additional prominent
abnormalities were present in both frontal lobes. NAA/
(Cr?Cho) abnormalities in TLE-no were more diffuse and
less well-deﬁned and were most prominent in the temporo-
insular and bilateral frontal regions. The direct compari-
sons between TLE-MTS and TLE-no showed no signiﬁcant
differences at the chosen signiﬁcance threshold.
Single subject analysis
Figure 3 displays the results of the single subject analysis
for two typical TLE-MTS and two typical TLE-no. Table 2
shows the results for each subject. Three TLE-MTS and
ﬁve TLE-no had no clusters with signiﬁcant NAA/
(Cr?Cho) reductions. The remaining nine TLE-MTS had
1–5 clusters with abnormally low NAA/(Cr?Cho) [average
number (No) of clusters: 2.7; median cluster size: 93,021
(range 1,193–602,663 voxels; median size of largest clus-
ter: 4,515 (range 1,193–5,85,555 voxels)], and the
remaining eight TLE-no had 1–7 clusters with abnormally
low NAA/(Cr?Cho) [average No of clusters: 4.0; median
cluster size: 11,287 (range 1,638–49,841) voxels; median
size of largest cluster: 4,828 (range 1,638–26,961 voxels)].
TLE-MTS and TLE-no did not differ from each other
regarding number of abnormal NAA/(Cr?Cho) clusters
nor regarding the size of these clusters or size of the largest
cluster.
The largest cluster of abnormally low NAA/(Cr?Cho)
was in the ipsilateral temporal lobe in ﬁve TLE-MTS. In
the remaining four TLE-MTS, the largest cluster with
abnormally low NAA/(Cr?Cho) was either in the contra-
lateral temporal lobe (n = 3) or contralateral (n = 1)
frontal lobe. In seven TLE-no the largest cluster with
abnormally low NAA/(Cr?Cho) was found in the contra-
lateral hemisphere (frontal: 3; insula: 2; parietal: 1, tem-
poral: 1) and in one it was found in the ipsilateral occipital
lobe.
Temporal lobe epilepsy with abnormally low NAA/
(Cr?Cho) did not differ from TLE with NAA/(Cr?Cho)
within the normal range regarding mean duration of epi-
lepsy (22.3 ± 17.5 vs. 20.3 ± 10.9 years, p = 0.74), age
at onset of epilepsy (19.5 ± 13.8 vs. 18.0 ± 13.5) occur-
rence of secondary generalized seizures (23.5 vs. 12.5%,
p = 0.47), occurrence of risk factors for epilepsy (35.3 vs.
37.5%, p = 0.71), seizures/month (7.5 ± 15.3 vs. 11.9 ±
14.8, p = 0.52) or % brain coverage by 3DEPSI (35.1 ±
8.2 vs. 39.3 ± 4.3%, p = 0.19).
Discussion
There were three major ﬁndings in this study: (1) Ipsi- and
contralateral temporal and extratemporal regions with
abnormally low NAA/(Cr?Cho) were found in TLE-MTS
and TLE-no. The extent of these NAA/(Cr?Cho) reduc-
tions varied between subjects even within the same
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these abnormalities, e.g., seizure frequency, type, were not
different between TLE with and without widespread NAA/
(Cr?Cho) reductions. (2) The high degree of interindi-
vidual heterogeneity and variability of the metabolic
abnormalities complicated the identiﬁcation of a distinct
pattern of NAA/(Cr?Cho) reductions in each of the two
TLE subgroups. Although the visual inspection of the TLE
vs. control comparisons suggested a predominantly tem-
poral-frontal distribution of the NAA/(Cr?Cho) decreases
in TLE-MTS and a more diffuse, less distinct distribution
in TLE-no (cf. Fig. 2), the two TLE groups were not sig-
niﬁcantly different from each other in the direct compari-
son. (3) Extrafocal NAA/(Cr?Cho) abnormalities did not
provide additional information for focus lateralization in
TLE-MTS or in TLE-no. Taken together, this study pro-
vides evidence that at least metabolically non-lesional TLE
is neither a focal nor a homogeneous disease.
Etiology of extrafocal NAA/(Cr?Cho) reductions
The ﬁrst ﬁnding of this study was the conﬁrmation of the
widespread, bilateral extrafocal NAA/(Cr?Cho) reductions
in TLE-MTS and TLE-no which had been described by
previous spectroscopic imaging studies with partial brain
coverage [12, 13]. The etiology of these extrahippocampal
NAA/(Cr?Cho) reductions in TLE is unknown. NAA
decreases in the hippocampus are usually thought to be
caused by neuron loss and/or neuronal dysfunction [9]. The
fact that hippocampal NAA decreases have been found to
Fig. 2 Regions with signiﬁcant
decreased NAA/(Cr?Cho) in
TLE-MTS compared to controls
(upper two panels) and TLE-no
compared to controls (lower two
panels). Abnormalities in TLE-
MTS were most prominent in
the bilateral temporal lobes but
extended also into posterior
occipital and frontal regions.
Abnormalities in TLE-no were
more diffuse, less distinct and
preferentially in bilateral
frontal, temporal-insular
regions. Similarly, as in the
single subject analysis, there
was no clear predominance of
the NAA/(Cr?Cho) reductions
in the ipsilateral hemisphere in
either group
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they are stable over time, at least in the epileptogenic
hippocampus. Neuronal loss and neuronal dysfunction
could also explain the extrahippocampal and extratemporal
NAA/(Cr?Cho) reductions found in this study. In analogy
to the focus, local excitotoxic effects of spreading epilep-
togenic activity could lead to neuronal loss in extrafocal
regions. In that case it could be expected that the resulting
NAA/(Cr?Cho) abnormalities are associated with struc-
tural abnormalities/volume loss. Widespread cortical thin-
ning in TLE-MTS and TLE-no with a similar distribution
as the NAA/(Cr?Cho) reductions described here has
indeed recently been demonstrated in a study from this lab
[16]. Extrafocal neuronal dysfunction could be caused by
deafferentation due to loss of input from the focus, or by
excitotoxic effects of seizure spread too mild to result in
neuronal loss. The best evidence that NAA/(Cr?Cho)
reductions due to neuronal dysfunction exist in TLE comes
from the observation that reduced NAA in the contralateral
hippocampus often returns to normal levels after successful
surgery [25, 26]. However, the observation that some of the
extrafocal NAA/(Cr?Cho) abnormalities are reversible
also indicates that the severity and extent of these NAA/
(Cr?Cho) reductions are not necessarily stable over time.
Longitudinal studies correlating extrahippocampal/extra-
temporal NAA/(Cr?Cho) changes with structural abnor-
malities and clinical variables, such as seizure frequency
between exams, will be necessary to explore in which
regions extrafocal NAA/(Cr?Cho) reductions are stable
over time and correspond to an irreversible neuron loss,
and in which regions they ﬂuctuate and indicate neuronal
dysfunction.
High intersubject variability of NAA/(Cr?Cho)
reductions in TLE-MTS and TLE-no
The single subject analysis showed a wide range of these
extrafocal NAA/(Cr?Cho) reductions even within the
same TLE group with some being metabolically com-
pletely normal while others had severe, widespread
abnormalities. The high degree of intersubject variability
of NAA/(Cr?Cho) abnormalities and the relatively small
population sizes made it difﬁcult to identify a distinct
pattern of metabolic abnormalities in each of the TLE-
subgroups (cf. Fig. 2). The most obvious explanation for
the variability of NAA/(Cr?Cho) reductions between
patients would be differences in severity and duration of
the epileptic disorder. Several studies have described a
relationship between structural abnormalities and duration
of epilepsy [27, 28]. Therefore, it could be expected that
TLE patients with a longer duration of epilepsy, more
frequent and/or more severe seizures (occurrence of sec-
ondary generalized seizures) have more severe NAA/
(Cr?Cho) reductions than subjects with less frequent and/
or milder seizures or who developed seizures later in life.
However, the direct comparison of metabolically normal
TLE with metabolically abnormal TLE provided no evi-
dence that any of these factors had an inﬂuence on the
severity of the NAA/(Cr?Cho) reductions. Technical
issues which could have caused such variations artiﬁcially,
i.e., differences in % brain coverage between metabolically
normal and abnormal subjects resulting in the exclusion of
regions with reduced NAA/(Cr?Cho) in the former but
inclusion in the latter, also seem unlikely since % brain
coverage was not different between subjects with normal
Fig. 3 Representative results of
the single subject analysis. The
two TLE-MTS had large
ipsilateral temporal clusters
which extended in neighboring
regions. There were also smaller
clusters in the frontal lobes. The
two TLE-no in general had
smaller and more diffusely
distributed clusters
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multitude of other potential factors which alone or in
combination might explain the wide range of NAA/
(Cr?Cho) abnormalities observed in non-lesional TLE,
e.g., interval between last seizure and scan [29], type of the
last seizure [30], type of antiepileptic medication, different
individual vulnerability for effects of epileptogenic activity
in non epileptogenic brain tissue, etc. Longitudinal studies
in a larger patient population might help to identify the
factors contributing to this variability.
Value of extrafocal NAA/(Cr?Cho) reductions
for focus lateralization
The lateralizing information provided by NAA/(Cr?Cho)
reductions in individual TLE-MTS patients was minimal.
Only 42% of the TLE-MTS had the largest cluster of
reduced NAA/(Cr?Cho) in the ipsilateral temporal lobe
and the hemispheric NAA/(Cr?Cho) reductions were not
signiﬁcantly different between the ipsi- and contralateral
hemispheres. The lateralizing information was even worse
for TLE-no. There were no signiﬁcant ipsi-/contralateral
hemispheric differences and the largest cluster of low
Table 2 Results of single subject analysis
Pat no. Group No. cluster Size cluster Side Lobe
1 MTS 0 0 na na
2 MTS 2 4,515 Contra Frontal
2,081 IPSI Temporal
3 MTS 5 35,365 IPSI Temporal
2,258 Contra Temporal
1,408 IPSI Frontal
2,342 Contra Frontal
1,420 IPSI Parietal
4 MTS 1 1,193 Contra Temporal
5 MTS 1 1,652 Contra Temporal
6 MTS 0 0 na na
7 MTS 5 9,708 IPSI Frontal
97,853 IPSI Temporal
12,774 Contra Frontal
1,784 Contra Temporal
5,487 Contra Frontal
8 MTS 1 1,295 IPSI Temporal
9 MTS 1 2,481 Contra Temporal
10 MTS 4 15,170 Contra Frontal
21,965 IPSI Temporal
3,773 Contra Temporal
10,002 Contra Parietal
11 MTS 4 6,609 IPSI Frontal
1,350 Contra Frontal
585,555 IPSI Temporal
9,149 Contra Temporal
12 MTS 0 0 na na
13 Norm 7 2,966 Contra Insula
1,147 Contra Temporal
1,303 IPSI Frontal
7,799 Contra Parietal
6,211 IPSI Occipital
1,326 Contra Frontal
2,239 IPSI Temporal
14 Norm 1 1,638 Contra Insula
15 Norm 0 0 na na
16 Norm 5 1,740 Contra Occipital
1,792 Contra Frontal
1,269 IPSI Frontal
1,257 Contra Temporal
1,587 IPSI Occipital
17 Norm 4 6,625 Contra Insula
2,062 IPSI Insula
2,625 IPSI Frontal
3,121 Bi Frontal
18 Norm 0 0 na Na
Table 2 continued
Pat no. Group No. cluster Size cluster Side Lobe
19 Norm 3 2,518 IPSI Frontal
2,708 Contra Parietal
2,915 Contra Frontal
20 Norm 0 0 na Na
21 Norm 4 2,532 IPSI Frontal
5,813 Contra Occipital
7,243 Contra Frontal
1,365 IPSI Temporal
22 Norm 1 3,030 IPSI Occipital
23 Norm 7 2,400 Contra Frontal
18,384 IPSI Occipital
3,983 Contra Frontal
18,552 Contra Temporal
3,102 Bi Frontal
2,228 Bi Frontal
1,192 IPSI Frontal
24 Norm 0 0 na na
25 Norm 0 0 na na
IPS ipsilateral, Contra contralateral, Bi bilateral, MTS mesial tem-
poral sclerosis, Norm normal, No. cluster number of clusters, Size
cluster number of voxels with abnormally low NAA/(Cr?Cho) in the
cluster, bold cluster which fulﬁll criterion for ‘‘focus as identiﬁed by
EPSI’’ and are concordant with EEG identiﬁcation of the focus
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123NAA/(Cr?Cho) were in all cases extratemporal. Based on
this, it can be concluded that extrahippocampal/extra-
temporal NAA/(Cr?Cho) reductions do not provide addi-
tional information for focus lateralization. Further study
will be needed to address the question if the extent and
distribution of these extrafocal NAA/(Cr?Cho) reductions
might be useful to predict post-surgical seizure control or
cognitive impairment.
Technical limitations
The study has limitations: (1) Loss of spectral data affected
particularly the basal and mesial temporal lobe, i.e., regions
which are prominently affected in TLE. Therefore, we may
have missed signiﬁcant temporal NAA/(Cr?Cho) reduc-
tions providing lateralizing information. This might also
explain why four patients (Pat No 4, 5, 9, 14) had only
contralateral abnormalities. Future studies should combine
3D EPSI with a single slice hippocampal measurement to
ensure that data is also consistently collected from these
regions. (2) For the reasons outlined in the methodological
sections, we used NAA/(Cr?Cho) maps and not single
metabolite maps. Therefore, we cannot exclude that some
of the metabolic abnormalities were caused by elevated
Cho and/or Cr concentrations rather than by NAA
decreases. (3) The study population was small and so lack
of statistical power might be responsible for some of the
negative ﬁndings, e.g., such as not ﬁnding signiﬁcant ipsi-/
contralateral differences. (4) All patients were recruited
from tertiary care centers where they were evaluated for
epilepsy surgery. These patients were probably suffering
from a more severe form of TLE and, thus, may not be
representative for non-lesional TLE in general. It will
therefore be necessary to replicate the ﬁndings in a larger,
more diverse TLE population. In addition to duration of
epilepsy, seizure frequency, etc., future studies should also
address the inﬂuence of other factors on extrafocal NAA/
(Cr?Cho) reductions, e.g., contribution of antiepileptic
treatment, correlation with extent of EEG abnormalities.
Conclusion
This study conﬁrmed the ﬁndings of previous spectroscopic
imaging studies which demonstrated wide spread extrafo-
cal NAA/(Cr?Cho) abnormalities in TLE-MTS and TLE-
no. The ﬁnding that extrafocal NAA/(Cr?Cho) reductions
show a considerable individual variation in extent and
severity within each of the subtypes demonstrates that a
homogeneous pattern of neuronal dysfunction/neuronal
loss does not exist in either TLE-MTS or TLE-no. Further
studies will be necessary to obtain a better understanding of
the nature of these metabolic abnormalities and of their
inﬂuence on cognitive performance and long term outcome
after epilepsy surgery.
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